BioNTech SE (BNTX)
108.23
+6.09
(+5.96%)
USD |
NASDAQ |
Nov 21, 16:00
108.77
+0.54
(+0.50%)
After-Hours: 20:00
BioNTech Gross Profit Margin (Quarterly): 85.63% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 85.63% |
June 30, 2024 | 53.54% |
March 31, 2024 | 68.50% |
December 31, 2023 | 87.89% |
September 30, 2023 | 81.93% |
June 30, 2023 | 2.86% |
March 31, 2023 | 92.48% |
December 31, 2022 | 95.71% |
September 30, 2022 | 78.25% |
June 30, 2022 | 76.08% |
March 31, 2022 | 79.70% |
December 31, 2021 | 89.46% |
September 30, 2021 | 80.10% |
Date | Value |
---|---|
June 30, 2021 | 83.35% |
March 31, 2021 | 88.62% |
December 31, 2020 | 88.13% |
September 30, 2020 | 89.93% |
June 30, 2020 | 86.57% |
March 31, 2020 | 78.70% |
December 31, 2019 | 84.02% |
September 30, 2019 | 85.24% |
June 30, 2019 | 78.71% |
March 31, 2019 | 87.75% |
December 31, 2018 | 92.98% |
September 30, 2018 | 86.38% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
2.86%
Minimum
Jun 2023
95.71%
Maximum
Dec 2022
78.57%
Average
83.68%
Median
Gross Profit Margin (Quarterly) Benchmarks
Novavax Inc | 28.27% |
DBV Technologies SA | -- |
Akari Therapeutics PLC | -- |
Biodexa Pharmaceuticals PLC | -- |
NuCana PLC | -- |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | -2.35% |
Return on Assets | -2.06% |
Return on Invested Capital | -2.32% |
Profit Margin (Quarterly) | 15.91% |
Operating Margin (Quarterly) | 0.84% |
Return on Net Operating Assets | -10.80% |